A semaglutida um medicamento antidiabtico (para tratar diabetes tipo 2), liberado pela Agncia Nacional de Vigilncia Sanitria (Anvisa) em 2018 para este objetivo no Brasil
JAMA 303:14101418 Pratley RE, Nauck M, Bailey T et al (2010) Liraglutide vs sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Glucagon Receptor Activity Retatrutide also activates glucagon receptors, making it distinct from many previous peptide candidates
Yes, that is perfectly normal
Long-term safety monitoring is still important because retatrutide may cause significant weight loss and affects several hormone pathways
Drug Interactions and Other Considerations Hypoglycaemia: Risk increases if combined with insulin or sulphonylureas